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Abstract
Physical inactivity is considered as one of the potential risk factors for the development of type 2 diabetes and other
metabolic diseases, while endurance exercise training could enhance fat oxidation that is associated with insulin sensitivity
improvement in obesity. AMP-activated protein kinase (AMPK) as an energy sensor plays pivotal roles in the regulation of
energy homeostasis, and its activation could improve glucose uptake, promote mitochondrial biogenesis and increase
glycolysis. Recent research has even suggested that AMPK activation contributed to endurance enhancement without
exercise. Here we report that the natural product arctigenin from the traditional herb Arctium lappa L. (Compositae) strongly
increased AMPK phosphorylation and subsequently up-regulated its downstream pathway in both H9C2 and C2C12 cells. It
was discovered that arctigenin phosphorylated AMPK via calmodulin-dependent protein kinase kinase (CaMKK) and serine/
threonine kinase 11(LKB1)-dependent pathways. Mice treadmill based in vivo assay further indicated that administration of
arctigenin improved efficiently mice endurance as reflected by the increased fatigue time and distance, and potently
enhanced mitochondrial biogenesis and fatty acid oxidation (FAO) related genes expression in muscle tissues. Our results
thus suggested that arctigenin might be used as a potential lead compound for the discovery of the agents with mimic
exercise training effects to treat metabolic diseases.
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Introduction
Physical inactivity is considered as one of the risk factors for the
development of type 2 diabetes and other metabolic diseases. It is
known that endurance exercise training could lead to fiber type
transformation, mitochondrial biogenesis, angiogenesis and other
adaptive changes in skeletal muscle [1,2], thus further enhancing
fat oxidation that is associated with improvement of insulin
sensitivity in obesity [3]. Currently, at least 60% of the global
population fails to achieve the daily minimum recommendation of
30 min moderate intensity of physical activity, and within these
people the risk of getting the related chronic diseases including
type 2 diabetes increases by 1.5 times [4]. Therefore, it has
become valuable to discover active agents that would mimic the
effects of exercise training to prevent or treat metabolic diseases.
AMP-activated protein kinase (AMPK) is a heterotrimeric
serine/threonine protein kinase with three subunits (a, b, c) [5]. As
the major molecular sensor for AMP/ATP ratio in cells, AMPK
plays a pivotal role in the regulation of energy metabolism [6].
AMPK activation switches on ATP-producing processes (such as
glucose uptake, mitochondrial biogenesis and glycolysis) and
inhibits ATP-consuming anabolic processes (such as protein
synthesis and sterol synthesis) [7]. AMPK phosphorylation is
regulated by a series of upstream AMPK kinases, including serine/
threonine kinase (LKB1) [8], Tak1 kinase and two calmodulin-
dependent protein kinase kinases (CaMKKa and CaMKKb)
[9,10].
Recently, it was reported that AMPK activation could improve
mice endurance in the absence of exercise training [11]. Under
endurance training condition, skeletal muscle suffers a number of
changes, such as glucose consumption decreasing, main energy
source transition from glucose to fatty acid utilization, mitochon-
drial biogenesis increasing and fiber-type switch [11,12]. AMPK
activation could increase peroxisome proliferator-activated recep-
tor-c coactivator-1a (PGC-1a) gene expression or the direct
phosphorylation of PGC-1a in skeletal muscle [6,13]. PGC-1a is
known to be involved in the regulation of mitochondrial
biogenesis, respiration, hepatic gluconeogenesis and other biolog-
ical processes by interaction with several transcription factors, such
as ERRa, NRF1, NRF2 and PPARs [14,15]. PGC-1a null mice
showed muscle dysfunction, abnormal weight control and hepatic
steatosis [16,17]. Although skeletal muscle was not an active
lipogenic organ as liver, exercise training or AMPK activation has
been also reported to promote fatty acid synthesis and oxidation as
evidenced by up-regulation of varied main enzymes such as
pyruvate dehydrogenase kinase 4 (PDK4), stearoyl-CoA desatur-
ase-1 (SCD-1), fatty acid synthetase (FAS) and muscle carnitine
palmitoyltransferase I (mCPT1b) within related pathways in
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energy than metabolism of glucose, and alteration of utilizing this
energy substrate could contribute to exercise tolerance [11,21].
Additionally, AMPK activation changes skeletal muscle myofiber
type composition, which mimics the fiber type switch induced by
endurance training [11,22]. Therefore, all the above findings
suggested that AMPK might act as a key mediator of endurance
training-induced changes, which was also confirmed further by the
result that treatment of AMPK agonist AICAR at a dose of
500 mg/kg/day could induce metabolic genes expression and
enhance running endurance [11].
Arctigenin (ATG, Fig. 1A) is a phenylpropanoid dibenzylbutyr-
olactone lignan extracted from the traditional herb Arctium lappa L.
(Compositae) with anti-cancer and anti-inflammatory effects [23–
26]. As a new type of antitumor agent, arctigenin could block the
unfolded protein response (UPR) by reducing the expression of
UPR-related genes, such as C/EBP homologous protein (CHOP),
activating transcription factor 4 (ATF4) and glucose-regulated
protein of 78 kDa (GRP78) under glucose deprivation [23–25]. Its
anti-inflammatory effect mainly acts by inhibiting type I-IV
allergic inflammation and pro-inflammatory enzymes in vitro and in
vivo [26].
In the present study, we discovered that arctigenin could
increase AMPK phosphorylation and up-regulate its downstream-
pathway related genes mRNA levels to promote mitochondrial
biogenesis and fatty acid synthesis and oxidation in vitro and in vivo,
subsequently leading to the mice treadmill endurance enhance-
ment. Cell based assay revealed that arctigenin increased AMPK
phosphorylation targeting the CaMKK and LKB1-dependent
pathways. Our results thus demonstrated that arctigenin might be
used as a lead compound for the discovery of the agents with
mimic exercise training effects to treat metabolic diseases.
Figure 1. Arctigenin (ATG) increased AMPK phosphorylation in H9C2 and C2C12 cells. A. Chemical structure of arctigenin. B. C H9C2 (B)
and differentiated C2C12 (C) cells were treated with indicated concentrations of arctigenin (0-40 mM) for 30 min, AMPK phosphorylation and total
AMPK levels were determined by western blotting. The results shown are representative of three independent experiments. The bands were
quantified using Image-Pro Plus software. Values are means 6 SE. *, p,0.05; ***, p,0.005; one-way ANOVA.
doi:10.1371/journal.pone.0024224.g001
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Arctigenin increased AMPK phosphorylation in H9C2 and
C2C12 cells
As reported, AMPK activation switched on ATP-producing
processes to enhance endurance [7,11]. With this information, we
thus constructed the phospho-AMPK activator screening platform
(Text S1), based on which our lab in-house natural product library
was screened out and the natural product arctigenin (Fig. 1A) was
finally identified to efficiently activate AMPK phosphorylation
(Fig. S1). As shown in Fig. 1B and C, arctigenin dose-dependently
increased AMPK phosphorylation in both H9C2 and C2C12
muscle cells, while had no effects on total AMPK.
Arctigenin activated PGC-1a transcription via up-
regulating AMPK phosphorylation
PGC-1a was known to act as the master regulator in
mitochondrial biogenesis and skeletal muscle adaptation [27–
29]. Since AMPK activation by actual exercise or pharmacological
treatment could lead to up-regulation of PGC-1a gene expression
[30,31], we investigated the potential effects of arctigenin on PGC-
1a mRNA level in both H9C2 and C2C12 cells. Compared with
DMSO-treated group, arctigenin incubation could dose-depen-
dently up-regulate PGC-1a mRNA levels in both cell lines
(Fig. 2A). By considering that AMPK phosphorylated PGC-1a
directly at theronine-177 and serine-538, which are required for
induction of PGC-1a promoter [6], we thus examined whether
arctigenin could increase PGC-1a transcription through regulating
its promoter activity by luciferase assay. As shown in Fig. S2A, the
relative PGC-1a promoter activity was highly increased in
arctigenin treated group compared with the DMSO group in
HEK293T cells.
PGC-1a as a key regulator in energy metabolism could respond
to varied physical stimuli, such as muscle contraction, cold stress
and overfeeding [32–35]. It could be regulated by AMPK, p38
MAPK or NF-kB pathway [11,36–38]. Since arctigenin has been
determined to increase AMPK phosphorylation and PGC-1a
transcription, we thus wondered whether the effect of arctigenin
on PGC-1a was dependent on its effect on AMPK. Therefore, we
examined the effects of arctigenin on PGC-1a mRNA level and
PGC-1a promoter activity together with AMPK inhibitor
compound C incubation in the related cells. As shown in
Fig. 2B–E and Fig. S2B, treatment of compound C almost
inhibited the arctigenin-induced AMPK phosphorylation and
completely blocked the arctigenin-induced up-regulation of PGC-
1a mRNA level and promoter activity, implying that the effect of
arctigenin on PGC-1a transcription regulation was dependent on
its role in AMPK phosphorylation.
These results thereby indicated that arctigenin could induce
PGC-1a transcription in skeletal muscle and cardiac muscle cell
lines via up-regulating AMPK phosphorylation.
Arctigenin increased mitochondrial biogenesis and fatty
acid oxidation genes expression
Since arctigenin has been determined to induce PGC-1a
transcription via up-regulating AMPK phosphorylation, this result
thereby implied that arctigenin might play a potential role in
promoting mitochondrial biogenesis and function. To further
evaluate this hypothesis, the mRNA levels of the related genes
were detected in both H9C2 and C2C12 cell lines with results
listed in Fig. 3A and B. Estrogen-related receptor a (ERRa), a
nuclear receptor activated by interacting with PGC-1a, was
reported to control the expression of nuclear genes encoding
mitochondrial proteins (NUGEMPs) [39,40]. We found ERRa
mRNA level was obviously elevated by arctigenin treatment. At
the same time, as a typical NUGEMP and significant component
of electron transport chain (ETC) in mitochondrial, cytochrome c
mRNA was also induced by arctigenin administration. Further-
more, as also indicated in Fig. 3A, arctigenin significantly activated
the mRNA levels of PDK4, SCD1, FAS and mCPT1b which are
key enzymes in fatty acid synthesis and oxidation for promotion of
energy source transforming from glucose to fatty acid in C2C12
cells at 40 mM, while the regulation of arctigenin in these genes
was not effectively in H9C2 cells for lack of significant difference in
SCD1 and FAS mRNA levels between high dose of arctigenin
administration group (40 mM) and DMSO control (Fig. 3B).
To clarify whether arctigenin regulated mitochondrial biogen-
esis and FAO related genes mRNA levels through its effect on
AMPK phosphorylation, we examined the influence of arctigenin
on these genes together with AMPK inhibitor (compound C)
incubation in C2C12 and H9C2 cells. As indicated in Fig. S3 and
S4, treatment of compound C almost inhibited the arctigenin-
induced genes expression except mCPT1b in H9C2 and SCD1 in
C2C12 cells. These results thus demonstrated that arctigenin
increased mitochondrial biogenesis and fatty acid oxidation genes
mRNA levels mainly through its effect on AMPK phosphoryla-
tion.
Therefore, all our results suggested that arctigenin could
activate PGC-1a transcription and increase mitochondrial bio-
genesis and fatty acid oxidation genes expression in both skeletal
muscle and cardiac muscle cells.
Arctigenin regulated the related genes expression not via
affecting transcriptional activity of PPARd
As reported, AMPK catalytic subunit over-expression evidently
promoted basal and ligand-dependent transcription of PPARd
[11], indicative of that PPARd might be also involved in AMPK
related gene expression. The fact that AICAR (AMPK activator)
synergistically increased mice endurance and gene expression with
GW501516 (PPARd agonist) further implied the potential of
AMPK-PPARd signaling axis. Here, we also examined whether
arctigenin could induce the related PPARd involved gene
expression with mammalian one-hybrid and transcriptional
activation assay systems. As shown in Fig. S5, arctigenin failed
to regulate the co-activator recruitment or transcriptional activity
of exogenous or endogenous PPARd.
Therefore, all above-mentioned results suggested that arctigenin
regulating the relative gene expression is related to the
enhancement of AMPK phosphorylation, while might not to the
promotion of PPARd transcriptional activity.
Arctigenin enhanced AMPK phosphorylation through
CaMKK and LKB1-dependent pathways
Considering that arctigenin could activate AMPK phosphory-
lation, we subsequently investigated the potential regulation of this
natural product against the relevant AMPK-involved pathways. As
determined, directly activating AMPK in an allosteric manner
and/or indirectly promoting Thr172 phosphorylation of AMPK
both contributed to the AMPK activation. Bear that in mind, we
examined the recombinant AMPK enzyme activity with or
without arctigenin incubation in vitro to investigate whether
arctigenin could influence the conformation of AMPK thus
inducing AMPK activity. As indicated in Fig. 4A, arctigenin had
no effect on the recombinant AMPK enzyme activity, while
AMPK agonist A-769662 as a positive control significantly
increased the phosphorylation of its substrate SAMS [41,42],
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PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e24224Figure 2. Arctigenin (ATG) increased PGC-1a transcription via enhancing AMPK phosphrylation. A. H9C2 cells and differentiated C2C12
cells were cultured with arctigenin or DMSO for 24 hours before harvest. Total RNA extraction, cDNA preparation and PGC-1a mRNA quantification
were performed as ‘‘Experimental Procedures’’. GAPDH mRNA was used as an internal control and data was shown as folded changes of blank
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activated AMPK.
As reported, AMPK has an obligate requirement for phosphor-
ylation by an upstream kinase on Thr-172 in the a-subunit
catalytic domain [5]. Since the above assay has indicated that
arctigenin activated AMPK in an indirect manner, we further
explored the potential signaling responsible for arctigenin-induced
AMPK activation. Regarding the fact that LKB1 and CaMKK
are within the main identified kinases in AMPK upstream
pathway and play pivotal roles in regulation of AMPK
phosphorylation [43], we thus addressed these two kinases related
assays. Firstly, we determined whether CaMKK activation was
necessary for arctigenin-induced AMPK phosphorylation. As
shown in Fig. 4B, pretreatment of HEK293T, a model cell usually
used in mechanism studies, with the selective CaMKK inhibitor
STO-609 [9] obviously attenuated the arctigenin-induced AMPK
phosphorylation. To investigate whether LKB1 pathway might
participate in the arctigenin-induced AMPK activation, we carried
out LKB1 knock-down assay in HEK293T cells as reported [44].
The results in Fig. 4C revealed that LKB1 knock-down in
HEK293T cells efficiently down-regulated the arctigenin-induced
AMPK phosphorylation.
Taken together, our results thereby suggested that arctigenin
stimulated AMPK phosphorylation via CaMKK and LKB1-
dependent pathways.
Arctigenin efficiently enhanced sedentary mice treadmill
endurance
AMPK was reported as an ‘‘exercise mimetic’’, whose
pharmacological activator-AICAR was ever tested to provide
several benefits of exercise in sedentary mice [11]. Since arctigenin
has been determined able to effectively activate AMPK phos-
phorylation, we thereby evaluated whether this natural product
could enhance mice endurance. To address this issue, we
performed the treadmill exhaustion test among the selected mice
(All mice were examined regarding the treadmill performance
before arctigenin administration, and those mice whose running
time was too long or too short compared with the average were
eliminated to reduce the potential effects by the inherent variation)
after 6-week arctigenin administration (8 mg/kg). Running time
and distance till fatigue were estimated as maximal endurance
capacity. As shown in Fig. 5A and B, arctigenin administration
brought on approximately an increase of 40% in mean fatigue
time and 65% in mean fatigue distance, further indicating that
arctigenin efficiently enhanced sedentary mice treadmill endur-
ance.
During the treatment, mice showed similar basal behavior, food
consumption and body weight (Fig. S6A and B). In addition, to
investigate the preliminary toxicity of arctigenin, TNFa and IL-6
levels in mice serum were tested. The results revealed that there
was no difference in those two inflammatory factors comparing
arctigenin with vehicle groups (Fig. S6C and D). At the same time,
aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) were also detected. As shown in Fig. S6E and F, no change
was found for AST while ALT elevated with arctigenin
administration, suggestive of the potential hepatotoxicity of
arctigenin in ip administration. Therefore, these results demon-
strated that arctigenin elevated sedentary mice endurance
efficiently while no significant toxicity was observed.
Arctigenin could not induce skeletal muscle fiber-type
changes
As reported, endurance exercise, AMPK mutation with
persistent activation and PGC-1a over-expression in transgenic
control. B. C. H9C2 cells (B) and differentiated C2C12 cells (C) were treated with or without 20 mM compound C for 1 hour before and during the
incubation with actigenin (20 mm) for 24 hours. After harvest, phospho- and total AMPK protein levels were analyzed. The bands were quantified
using Image-Pro Plus software. Values are means 6 SE. D. E. H9C2 (D) and differentiated C2C12 cells (E) were treated with or without 20 mM
compound C for 1 hour before and during the incubation with actigenin (20 mM) for 24 hours. Total mRNA was extracted and PGC-1a mRNA level
quantified. The results shown are representative of three independent experiments. *, p,0.05; **, p,0.01; ***, p,0.005; one-way ANOVA. #,p ,0.05;
###,p ,0.005: for compound C and arctigenin co-incubation group versus arctigenin treated group; student’s t test.
doi:10.1371/journal.pone.0024224.g002
Figure 3. Arctigenin (ATG) promoted mitochondrial biogenesis and FAO related gene expression. A. B. H9C2 and differentiated C2C12
cells were treated with indicated concentration of arctigenin (1, 10, 40 mM) or DMSO for 24 hours before harvest. Total RNA extraction, cDNA
preparation and ERRa, cytochrome c, SCD1, PDK4, FAS, and mCPT1b mRNA quantification were performed as ‘‘Experimental Procedures’’. GAPDH
RNA was used as an internal control for calculating mRNA fold changes. The results shown are validated by three independent experiments.
*, p,0.05; **, p,0.01; ***, p,0.005; one-way ANOVA.
doi:10.1371/journal.pone.0024224.g003
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induce myofiber type switch [12,22,45]. We thereby considered
that arctigenin might change myofiber type construction in
skeletal muscle tissues. However, we failed to find any obvious
conversions in the mRNA levels of four different myosin heavy
chain (MHC) isoforms (MHCI as a marker to represent type I
myofibers, MHCIIa, MHCIIx and MHCIIb as markers to
represent type II myofibers) in gastrocnemius (Fig. 5C) and
quadriceps (Fig. 5D) comparing arctigenin administration group
with vehicle group. Additionally, no obvious changes were found
in myofibers compositions between arctigenin treatment group
and vehicle group in ATPase staining (Fig. S7). These results thus
suggested that arctigenin could not affect myofiber type
proportion.
Figure 4. Arctigenin (ATG) enhanced AMPK phosphorylation through CaMKK and LKB1-dependent pathway. A. Arctigenin was pre-
incubated with AMPK a2b1c1 for 30 min, AMPK activity was measured by monitoring the produced ADP with A-769662 as a positive control. B.
HEK293T cells were treated with arctigenin (10 mM) in the absence or presence of STO-609 (2 mg/ml, pre-incubation for 4 h in serum-free DMEM) for
30 min in serum-free DMEM. AMPK phosphorylation and total AMPK levels were determined by western blotting. C. After transfected with
pSuper.neo.gfp-LKB1 for 48 hours, HEK293T cells were treated with arctigenin (20 mM) for 30 min. AMPK phosphorylation and total AMPK levels were
determined by Western blotting. The bands were quantified using Image-Pro Plus software. Values are means 6 SE. Values are means 6 SE. The
results shown are representative of three independent experiments. *, p,0.05; **, p,0.01; ***, p,0.005; student’s t test.
doi:10.1371/journal.pone.0024224.g004
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mitochondrial biogenesis and FAO pathway in vivo
To further investigate the potential regulative mechanism of
arctigenin regarding its improvement of mice treadmill endurance,
we addressed the relevant tissue-based assays. Compared with
vehicle group, arctigenin (8 mg/kg) administration enhanced
AMPK phosphorylation in gastrocnemius (Fig. 6A), quadriceps
(Fig. 6B) and cardiac muscles (Fig. 6C). The results shown in
Fig. 6D–F suggested that arctigenin up-regulated the mRNA levels
of PGC-1a and ERRa and the protein levels of cytochrome c in
gastrocnemius, quadriceps and cardiac muscles. Additionally,
mRNA levels of SCD1, PDK4 and mCPT1b were also
determined to be obviously elevated in gastrocnemius and
quadriceps muscles with arctigenin treatment, consistent with the
cell based results. Notably, there was also a tendency for higher
average FAS mRNA levels in arctigenin treated group but without
significance. To further identify the regulation of arctigenin on
FAO pathway, the protein level of uncoupling protein 3 (UCP3)
that is also involved in FAO induction [46] was examined. As
shown in Fig. 6A–C, UCP3 expression was obviously elevated in
gastrocnemius and quadriceps muscles.
As fatty acid synthesis and storage related genes were up-
regulated, we thereby hypothesized that arctigenin treated mice
might contain more fatty acid in skeletal muscle for instant
oxidation to supply energy source during exercise. Bearing that in
mind, we thus detected fatty acid levels in skeletal muscles
(gastrocnemius and quadriceps) and found that arctigenin
treatment could enhance fatty acid storage in gastrocnemius
evidently while in quadriceps without significance (Fig. S8A and
B).
Therefore, all those in vitro and in vivo results thereby suggested
that arctigenin could enhance AMPK phosphorylation, mitochon-
Figure 5. Arctigenin (ATG) elevated mice treadmill performance without inducing myofiber type conversion in skeletal muscle. A. B.
After mice were administrated with arctigenin (8 mg/kg) or vehicle via intraperitoneal for a period of 6 weeks, they were run to fatigue on a treadmill
as ‘‘Experimental Procedures’’. Running time and distance were recorded (n=8/group). Values are means 6 SD. C. D. Total RNA was extracted from
gastrocnemius and quadriceps, and type I and type II MHCs were then analyzed by real-time PCR assays (n=10/group). GAPDH RNA was used as an
internal control for calculating mRNA fold changes. ***, p,0.005; student’s t test.
doi:10.1371/journal.pone.0024224.g005
Arctigenin Enhances Mice Endurance
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e24224drial biogenesis and FAO pathway related genes expression, finally
leading to the enhancement of exercise-free endurance.
Discussion
Over the past decades, aerobic endurance exercise has been
potently highlighted concerning its significance in the clinical
amelioration of many disease symptoms, such as glucose
metabolism in type 2 diabetes [47], dyslipidemia in atherosclerosis
[48] and hypertension in stroke, acute myocardial infarction or
cardiac insufficiency [49,50]. Nevertheless, the inability to afford
definite intensity of physical exercise has been always the obstacle
to make profits of exercises [51]. Discovery of active agents that
would mimic the reprogramming metabolism induced by exercise
training is one of the effective strategies to overcome these
obstacles.
Actual exercises could result in activation of kinases/phosha-
tases signaling pathway, nuclear translocation of transcription/
translation factors, up-regulation of NUGEMPs and mtDNA-
encoded proteins, and augmentation of muscle aerobic capacity
[52]. AMPK is activated during physical activities to promote
down-stream metabolic reprogramming (e.g. mitochondria bio-
genesis, fatty acid oxidation promotion and myofiber type switch),
and considered as a significant mediator in skeletal muscle
adaptations [6,7,22]. Therefore, pharmacological activation of
AMPK may provide benefits of endurance exercise without actual
physical activities, which was ever confirmed by endurance
enhancing activity of its activators AICAR [11]. It was found that
AMPK activator-AICAR, which is metabolized to an AMP
mimetic in cell, could increase sedentary mice treadmill endurance
at a high dosage of 500 mg/kg/day via intraperitoneal injection
and up-regulate genes linked to oxidation metabolism via AMPK-
PPARd signaling axis [11]. Resveratrol, a natural polyphenolic
product derived from grapes, could also increase mice aerobic
capacity without exercise at a dose of 400 mg/kg/day orally [53]
targeting SIRT1 and subsequently regulating its downstream
pathway, which was reported to tightly couple with AMPK [54].
Compared with synthetic compounds, small molecules from
natural sources are featured by their large-scale of structure
diversity [55]. Therefore, we performed the screening of the
efficient phosphor-AMPK activator targeting our in-house natural
product library and finally discovered that arctigenin dose-
dependently increased AMPK phosphorylation in vitro (Fig. 1B
and C) and in vivo (Fig. 6A–C).
Arctigenin was extracted from Arctium lappa L., which has been
widely used in traditional Chinese medicine [56]. Previous studies
have illustrated that arctigenin was active in anti-viral infection,
anti-tumor, anti-inflammation, and neuroprotection [23–26,57–
59]. Here we reported that arctigenin promoted AMPK
phosphorylation on Thr172 site through CaMKK and LKB1-
Figure 6. Arctigenin (ATG) enhanced AMPK phosphorylation, mitochondrial biogenesis and FAO pathway in vivo. A. B. C. Protein
levels of p-AMPK, t-AMPK, UCP3 and cytochrome c were determined by western blotting in gastrocnemius (A), quadriceps (B) and cardiac muscle (C).
(n=5/group). The bands were quantified using Image-Pro Plus software. Values are means 6 SE. D. E. F. Relative gene mRNA levels (PGC-1a, ERRa,
cytochrome c, SCD1, mCPT1, PDK4, FAS) from gastrocnemius (D), quadriceps (E) and cardiac muscle (F) were analyzed by real-time PCR assays (n=10/
group). GAPDH RNA was used as an internal control for calculating mRNA fold changes. *, p,0.05; **, p,0.01; student’s t test.
doi:10.1371/journal.pone.0024224.g006
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phosphorylation was also reported involving in regulation of
AMPK activity [60,61]. To clarify whether arctigenin could affect
AMPK phosphorylation on Ser485/491, we examined Ser485/
491 phosphorylation levels of AMPK in arctigenin treated cells. As
shown in Fig. S9, arctigenin did not change AMPK Ser485/491
phosphorylation in HEK293T, H9C2 or C2C12 cell lines,
implying that arctigenin activated AMPK phosphorylation on
Thr172 without impacting AMPK Ser485/491 phosphorylation.
We also found that arctigenin significantly enhanced sedentary
mice running endurance at a dose of 8 mg/kg/day (Fig. 5A and
B). Furthermore, cytochrome c protein and mRNA levels were
typically increased in mitochondrial biogenesis, and FAO related
genes (SCD1, PDK4, FAS and mCPT1b) mRNA levels were also
obviously elevated in muscle tissues (Fig. 6). Fatigue induced by
treadmill running was primarily developed from periphery tissues
and featured by rapid clearance of intracellular ATP and relative
insufficiency of oxidation metabolism in cardiovascular and
skeletal muscle system [62]. We thus concluded that promotion
of mitochondrial biogenesis and FAO linked gene expression
induced by arctigenin attributed to mice prolonged running time
and distance.
Myofiber type switch induced by endurance training was ever
considered as one of the reasons for exercise tolerance [12,22,45],
but we could not find any differences of fiber type composition in
skeletal muscle tissues (gastrocnemius and quadriceps) between
arctigenin-treatment and vehicle groups (Fig. 5C–D and Fig. S5).
Compared with AMPK persistent activating mutation that led to
myofiber type switch in vivo [45], the indirect phosphorylation of
AMPK by arctigenin might only share part of the down-stream
genes response with AMPK persistent activating mutation, which
resulted in unchangeable myofiber type composition in arctigenin
administrated group. Meanwhile, PGC-1a was also reported
playing a pivotal role in myofiber type transformation via
activating calcineurin signaling pathway [22]. Although arctigenin
obviously up-regulated PGC-1a transcription in vitro (Fig. 2A and
B) and in vivo (Fig. 6D–F), it might not mobilize calcium/
calcineurin pathway or totally activate PGC-1a interaction with
related proteins for promotion of the myofiber type switch. It is
noted that arctigenin up-regulated mitochondrial biogenesis
related genes (such as ERRa and cytochrome c) both in cardiac
and skeletal muscle tissues, but elevated FAO related genes only in
skeletal muscle tissues, which might be tentatively attributed to the
tissue specificity responding to arctigenin in fatty acid metabolism.
In summary, we demonstrated that arctigenin could efficiently
increase rodent sedentary treadmill endurance via enhancing
AMPK phosphorylation. This natural product induced the
accommodation of mitochondrial biogenesis and FAO pathway to
promote mitochondrial oxidative capacity without actual physical
activities as summarized in Fig. 7. Our results have provided
additionalunderstandingofpharmacologicalfunctionsforarctigenin
and traditional Chinese medicine Arctium lappa L., and suggested the
potential of arctigenin as a lead compound for anti-chronic
metabolic disease (e.g. obesity or type 2 diabetes) drug discovery.
Materials and Methods
Ethics Statement
All animal experiments were carried out in accordance with the
Regulations of Experiments Animal Administration issued by the
State Committee of Science and Technology of the People’s
Republic of China. Permit numbers: SCXK (HU) 2008-0017;
SYXK (HU) 2008-0049. This study was approved by Science and
Technology Commission of Shanghai Municipality.
Materials
Restriction enzymes were purchased from New England
Biolabs. Cell culture plastic ware was purchased from Corning
Inc. DMEM, fetal bovine and horse serums were purchased from
Invitrogen. Compound C and STO609 were obtained from
Sigma. Calcium Phosphate Cell Transfection Kit was obtained
from Beyotime. RNAiso, RT reagent Kit and SYRB Premix Ex
Taq were purchased from TaKaRa. Dual Luciferase Assay System
was obtained from Promega. Anti-cytochrome c, anti-phospho-
AMPK (Thr172), anti-AMPKa1/a2, and anti-LKB1 antibodies
were purchased from Cell Signaling Technology. Anti-CaMKK
antibody was purchased from Senta Cruz Biotechnology.
HEK293T, H9C2 and C2C12 cells were obtained from ATCC.
Cell culture and differentiation
As a typical cardiac muscle cell line, H9C2 was derived from
embryonic BD1X rat heart tissue and not differentiated in our
study. C2C12 was a subclone of the mouse myoblast cell line and
differentiated in DMEM with 2% horse serum, forming contractile
myotubes and expressing characteristic muscle proteins. Differen-
tiated myotubes were used in our experiments.
H9C2 and C2C12 cell lines were maintained in DMEM
supplemented with 10% fetal bovine serum and the cells were
grown at 37uC in an environment of 5% CO2. To induce
myoblast fusion and myotubes differentiation, C2C12 myoblasts
were switched to differentiation medium when 100% confluent in
6-well plate. Differentiation medium was exchanged every 2 days
for 6 days before experimental manipulation.
Western Blot analysis
Tissues were lysed with lysis buffer containing 25 mmol/L Tris-
HCl (PH 7.5), 150 mmol/L NaCl, 1 mmol/L Na3VO4,1 %
Triton X-100 and a protease inhibitor cocktail (Sigma-Aldrich).
Protein concentrations were determined using a BCA protein
Figure 7. A proposed model demonstrating arctigenin (ATG)-
induced endurance enhancement mechanism. Arctigenin in-
duced AMPK phosphorylation via CaMKK and LKB1 pathways, resulting
in PGC-1a up-regulation. Phosphorylated AMPK and PGC-1a activated
fatty acid synthesis and oxidation. Meanwhile, PGC-1a co-activated
ERRa to promote mitochondrial biogenesis. Promotion of mitochondrial
biogenesis and FAO led to activated aerobic capacity.
doi:10.1371/journal.pone.0024224.g007
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supernatants of the whole cell extracts were fractionated by SDS-
PAGE and transferred to Hybond-c nitrocellulose membrane
(Amersham Bioscience). The membranes were blocked for one
hour at room temperature and then incubated overnight at 4uCi n
TBST buffer (5% milk) containing related antibody. The
membranes were then incubated for an hour at room temperature
in TBST buffer (5% milk) containing anti-rabbit IgG or anti-
mouse IgG (Jackson-ImmunoResearch, West Grove, PA). Blots
were visualized by incubation with SuperSignal West Dura
chemiluminescence kit (Pierce Biotechnology) and exposing to
light-sensitive film.
The bands were quantified as ‘‘intensity6area’’ using Image-
Pro Plis software (MediaCybernetics) and statistically analyzed. SE
was calculated from three repeats of the experiments or five
individuals of arctigenin treated and vehicle groups.
RT-PCR and quantitative real-time PCR
Total RNA was extracted from administrated cells or mice
tissues using RNAiso (TaKaRa) reagent in accordance with the
Kit instruction. cDNA was synthesized by RT reagent Kit
(TaKaRa) and real-time PCR was performed using SYRB Premix
Ex Taq (TaKaRa) on DNA Engene Opticon TM2 system (MJ
Research, Waltham, MA, USA). The primers were listed as
follows:
PGC-1a: sense 59- gcccggtacagtgagtgttc-39, anti 59- ctgggccgtt-
tagtcttcct-39.
ERRa: sense 59- ctcagctctctacccaaacgc-39, anti 59- ccgcttggt-
gatctcacactc-39.
Cytochrome c: sense 59- cagcttccattgcggacac-39, anti 59- ggcac-
tcacggcagaatgaa-39.
PDK4: sense 59- agggaggtcgagctgttctc-39, anti 59- ggagtgttcacta-
agcggtca-39.
FAS: sense 59- ggaggtggtgatagccggtat-39, anti 59- tgggtaatccata-
gagcccag-39.
mCPT1b: sense 59- tgggactggtcgattgcatc-39, anti 59- tcagggttt-
gtcggaagagaga-39.
SCD1: sense 59- ttcttgcgatacactctggtgc-39, anti 59- cgggattgaa-
tgttcttgtcgt-39.
GAPDH: sense 59- acagcaacagggtggtggac-39, anti 59- tttgagggtg-
cagcgaactt-3.
MHCI: sense 59- ccttggcaccaatgtcccggctc-39, anti 59- gaagcg-
caatgcagatgcggtg-3.
MHCIIa: sense 59- atgagctccgacgccgag-39, anti 59- tctgttagcat-
gaactggtaggcg-3.
MHCIIx: sense 59- aaggagcaggacaccagcgccca-39, anti 59- atct-
ctttggtcactttcctgct-3.
MHCIIb: sense 59- gtgatttctcctgtcacctctc-39, anti 59- ggaggaccg-
caagaacgtgctga-3.
Luciferase assay
For evaluation of the effects of arctigenin on PGC-1a promoter,
HEK293T cells (24-well plate) were transfected with pGL3-PGC-
1a-luc together with PRL-SV40 and refreshed with normal
medium 5 hours later. After transfection, HEK293T cells were
incubated with indicated concentration of arctigenin for 24 h.
Luciferase activity was measured using Dual Luciferase Assay kit.
AMPK enzymatic activity assay
The recombinant AMPK activity was assayed using the
modified conventional approach in non-radioactive way (such as
Jun N-terminal kinase 2 (Jnk2a2), casein kinase 1, Protein kinase A
(PKA), etc.) [63], as outlined in Fig. S10.
In the assay, the substrate SAMS was used according to the
literature methods [41,42]. The recombinant AMPK isoform
a2b1c1 was purchased from Invitrogen. AMPK was diluted to
400 ng/ml in assay buffer (pH 7.4, containing 15 mM HEPES,
20 mM NaCl, 1 mM EGTA, 0.02% Tween) and pre-incubated
with arctigenin (0.2, 2, 20 mM) or A-769662 (1 mM) for 30 min on
ice. The kinase reaction was initiated by adding ATP (50 mM) and
SAMS (50 mM) at room temperature for 30 min. The produced
ADP reflecting the AMPK enzyme activity was thus measured by
the ADP Hunter Plus Assay kit (DiscoverX), and the fluorescent
signal was detected with an M5 Multi-Detection Reader using
excitation and emission wavelengths of 530 and 590 nm.
Animal experiment
C57BL/6J male mice at 6 weeks of age were purchased from
ShanghaiExperimental Animal Center, Chinese AcademyofSciences,
and acclimated to SPF microisollators for 2 days before any
experimental intervention. Mice were accommodated under standard
conditions (strict 12:12-h light-dark cycle, 22uC, 60% humidity) in
plastic cages and provided with water and food ad libitum.
All 30 mice were adapted to treadmill running for 10 min at
10 m/min at week -1 (5 days/week) avoiding unexpected accidents
and the first fatigue test was conducted at week 0. For fatigue test,
mice ran at 10 m/min for 5 min and 15 m/min for 10 min. After
the initial warm-up period, exercise intensity was increased by 5 m/
min every 30 min from 20 m/min until mice could not be
prompted to continue running by moderate electric stimulation
(less than 0.1 milliampere) and stayed at electrode for at least 10 sec.
After the first fatigue test, 20 mice with moderate endurance
capacity were selected from total 30 mice and divided into
arctigenin administration and vehicle treatment groups (n=10/
group). Before final fatigue assay, sedentary mice were treated with
arctigenin (8 mg/kg, body weight/day) or vehicle (sterilized 0.9%
Sodium Chloride containing 5% Tween-80) daily via intraperito-
neal injection for 6 weeks. Mice endurance capacity was estimated
by treadmill (Litai Science and Technology Inc. Exer6, Hangzhou,
China)running timeand distanceuntilfatigue [11,62]. After6-week
arctigenin administration, the last fatigue test was performed
according to the same protocol as before (n=8/group). For
investigation of the relevant gene changes in tissues, two mice in
each group as control were chosen escaping the fatigue test.
Tissue collection
Animals were euthanized 72 h after the last bout of exercise.
Gastrocnemius, quadriceps and heart muscles were thus isolated,
frozen, and stored at 280uC until further analysis.
Statistical analysis
All data were reported as mean 6 standard deviation of the
mean (SD). Data were analyzed in either one-way ANOVA with
an appropriate post hoc test for comparison of multiple groups or
unpaired student’s t test for comparison of two groups as described
in figure legends (Graphpad Prism software).
Supporting Information
Figure S1 Arctigenin (ATG) enhanced AMPK phosphor-
ylation in HEK293T cells. HEK293T cells were incubated with
indicated concentrations of arctigenin (0-40 mM) for 30 min, phospho-
and total AMPK were then detected by western blotting. The results
shown are representative of three independent experiments. The bands
were quantified using Image-Pro Plus software. Values are means 6
SE. **, p,0.05; ***, p,0.005; one-way ANOVA.
(TIF)
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tion via up-regulating AMPK phosphorylation. A. When
the confluence reached 30,40% (24-well plate), HEK293T cells
were transiently transfected with pGL3-PGC-1a promoter-Luc
and SV40. 5 hours later, cells were refreshed with medium
supplemented with arctigenin (1, 10, 40 mM) or DMSO and
incubated for 24 hours before Luciferase assays as described in
‘‘Materials and methods’’. B. After transfection, HEK293T cells
were administrated with or without 20 mM compound C for
1 hour before and during the incubation with actigenin (40 mM)
for 24 hours before Luciferase assays as described in ‘‘Materials
and methods’’. **, p,0.01. ##,p ,0.01: for compound C and
arctigenin co-incubation group versus arctigenin treated group;
student’s t test.
(TIF)
Figure S3 Effects of arctigenin (ATG) on ERRa, cyto-
chrome c, PDK4, SCD1, FAS and mCPT1b were
subjective to AMPK phosphorylation in H9C2. H9C2 cells
were treated with or without 20 mM compound C for 1 hour
before and during the incubation with actigenin (20 mM) for
24 hours. After harvested, mRNA levels of ERRa (A), cytochrome
c (B), SCD1 (C), PDK4 (D), FAS (E) and mCPT1b (F) were
analyzed. The results shown are representative of three indepen-
dent experiments. Values are means 6 SD. *, p,0.05. #,p ,0.05:
for compound C and arctigenin co-incubation group versus
arctigenin treated group; student’s t test.
(TIF)
Figure S4 Effects of arctigenin (ATG) on ERRa, cyto-
chrome c, PDK4, SCD1, FAS and mCPT1b were
subjective to AMPK phosphorylation in C2C12. Differen-
tiated C2C12 cells were administrated with or without 20 mM
compound C for 1 hour before and during the incubation with
actigenin (20 mM) for 24 hours. After harvested, mRNA levels of
ERRa (A), cytochrome c (B), SCD1 (C), PDK4 (D), FAS (E) and
mCPT1b (F) were analyzed. The results shown are representative
of three independent experiments. Values are means 6 SD.
*, p,0.05; **, p,0.01; ***, p,0.005. #,p ,0.05; ##,p ,0.01;
###,p ,0.005: for compound C and arctigenin co-incubation
group versus arctigenin treated group; student’s t test.
(TIF)
Figure S5 Arctigenin (ATG) failed to regulate the co-
activator recruitment and transcriptional activity of
PPARd.A . HEK293T cells were transfected with UAS-TK-
Luc, pCMX-Gal4DBD-PPARd-LBD and pRL-SV40 followed by
treatment of DMSO, GW501516 (PPARd agonist), and varied
concentrations of arctigenin for 24 hours. B. HEK293T cells were
transfected with pAdTrack-PPARd, pcDNA3.1-RXRa, pSV-
PPRE-Luc and pRL-SV40 and then incubated with DMSO,
GW501516 (PPARd agonist), and varied concentrations of
arctigenin for 24 hours. C. HEK293T cells were transfected with
pSV-PPRE-Luc and pRL-SV40, and incubated with DMSO,
GW501516 (PPARd agonist), and varied concentrations of
arctigenin for 24 hours. Relative luciferase activities were
measured as described in Text S1. The results shown are
representative of three independent experiments. Values are
means 6 SD. *, p,0.05; **, p,0.01; ***, p,0.005; one-way
ANOVA.
(TIF)
Figure S6 Effects of arctigenin (ATG) on diet, weight,
inflammation and liver toxicity of mice. A. Daily food
intake of each group was analyzed (n=10/group). B. Weight
change in each group was measured (n=10/group). C. D. Serum
from mice in each group was collected and levels of TNFa (C) and
IL-6 (D) were analyzed (n=10/group). E. F. Activities of ALT (E)
and AST (F) were measured (n=10/group). Values are means 6
SE. *, p,0.5; **, p,0.01; student’s t test.
(TIF)
Figure S7 Arctigenin (ATG) failed to induce skeletal
muscle fiber-type change. Metachromatical staining of frozen
cross-sections from gastrocnemius and quadriceps in vehicle and
arctigenin treated groups. The results shown are representative of
three independent experiments. Dark-brown stained type I fibers
were indicated by arrows.
(TIF)
Figure S8 Arctigenin (ATG) enhanced fatty acid storage
in gastrocnemius. Free fatty acid in gastrocnemius (A) or
quadriceps (B) of each group was analyzed (n=7/group). Values
are means 6 SD. *, p,0.5; student’s t test.
(TIF)
Figure S9 Arctigenin (ATG) failed to impact the phos-
phorylation of AMPK on Ser485/491 sites. HEK293T,
H9C2 and differentiated C2C12 cells were incubated with
indicated concentrations of arctigenin (0–40 mM) for 30 min,
AMPK (Thr172), AMPK (Ser485/491) and total AMPK were
then detected by western blotting. The results shown are
representative of three independent experiments.
(TIF)
Figure S10 A scheme demonstrating recombinant
AMPK activity assay approach.
(TIF)
Text S1 Supporting documents.
(DOC)
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